{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-014015","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.074501+00:00","generated_at":"2026-06-08T07:42:13.316666+00:00","sec_items":["2.02","4.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dermata Therapeutics appoints Moss Adams as auditor, reports $6.6M cash, advances DMT310 to Phase 3","bullets":["Appointed Moss Adams LLP as new auditor for FY2023, effective Nov 9, 2023, replacing MHM.","Cash and cash equivalents $6.6M as of Sep 30, 2023; expects to fund operations into Q2 2024.","Received positive FDA feedback on End of Phase 2 meeting for DMT310; agreed Phase 3 program acceptable for NDA filing.","Completed start-up activities for DMT310 Phase 3 STAR-1 trial; plans to initiate before end of 2023 after FDA protocol approval.","Q3 2023 R&D expenses $0.9M (down from $1.6M YoY); G&A expenses flat at $0.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-014015","json":"https://secwatch.observer/filing/0001654954-23-014015.json","markdown":"https://secwatch.observer/filing/0001654954-23-014015.md","text":"https://secwatch.observer/filing/0001654954-23-014015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423014015/0001654954-23-014015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423014015/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:42:13.316666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5e4a0e787eda8ceaa50985ddd883e5401cd2ba3","claim":"Dermata Therapeutics, Inc. engaged Moss Adams LLP as its auditor.","evidence_excerpt":"On November 9, 2023, the Audit Committee appointed Moss Adams LLP (“ Moss Adams ”) as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423014015/0001654954-23-014015-index.htm","confidence":0.95,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Moss Adams LLP"}],"fact_type":"auditor_change"},{"claim_id":"b5ab9c8441eacbbc9cb854fe619100502a07c737","claim":"Dermata Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423014015/0001654954-23-014015-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}